1. Iiizumi M, Liu W, Pai SK, Furuta E, Watabe K. Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta. 2008;1786(2):87–104.
2. Perret GY, Crepin M. New pharmacological strategies against metastatic spread. Fundam Clin Pharmacol. 2008;22(5):465–92.
3. Steeg PS. Heterogeneity of drug target expression among metastatic lesions: lessons from a breast cancer autopsy program. Clin Cancer Res. 2008;14(12):3643–5.
4. Steeg PS, Anderson RL, Bar-Eli M, Chambers AF, Eccles SA, Hunter K., Itoh K., Matrisian LM, Sleeman JP, Theodorescu D., Thompson EW, Welch DR. Preclinical drug development must consider the impact on metastasis. Clin Cancer Res. 2009;15(14):4529–30.
5. Gura T. Systems for identifying new drugs are often faulty. Science. 1997;278(5340):1041–2.